What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NEO-1306, Multiple Dose #1, single dose once per day for 14 days”In the company’s words, NCT07948447 on ClinicalTrials.gov
- Tested for
- IBD (Inflammatory Bowel Disease)
- Main trialPhase 1
- “NEO-1306 is being developed for the treatment of moderately to severely active inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). This will be the first study - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO-1306 in Healthy Participants.”In the company’s words, NCT07948447 on ClinicalTrials.gov
Other drugs for IBD (Inflammatory Bowel Disease)
- ObefazimodAbivax S.A. · Phase 3
- TofacitinibPfizer · Phase 3
- RisankizumabAbbVie · Phase 3
- UpadacitinibAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
Coming up1
- May 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 19 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07948447
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | May 2027 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NEO 1306 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026